Concepedia

Cecilia Scimia

CS

Statistics

Publications

4

Citations

134

H-Index

4

Active since

2021

Affiliations

Rhythm (United states)(Current)

Jazz Pharmaceuticals (United States)

Wellcome/MRC Institute of Metabolic Science

University of Florida

Cecilia Scimia is an author at Rhythm (United states) specializing in medicine, weight management, and obesity treatment.

Publications per year

2021–2024

4

Publications

4

Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

Christian L. Roth, Cecilia Scimia, Ashley H. Shoemaker et al. · The Lancet Diabetes & Endocrinology · 2024 · 58 citations

, , +11

Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial

Jesús Argente, Charles F. Verge, Uzoma Okorie et al. · The Lancet Diabetes & Endocrinology · 2024 · 40 citations

, , +8

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK‐906), a dopamine D<sub>2</sub>/D<sub>3</sub> receptor antagonist, in patients with gastroparesis

Braden Kuo, Cecilia Scimia, George E. Dukes et al. · Alimentary Pharmacology & Therapeutics · 2021 · 26 citations · Full text

, , +16

Effects of Setmelanotide in Patients With POMC, PCSK1, or LEPR Heterozygous Deficiency Obesity in a Phase 2 Study

I. Sadaf Farooqi, Jennifer L. Miller, Olga Ohayon et al. · Journal of the Endocrine Society · 2021 · 10 citations · Full text

, , +15

1–4 of 4